dc.contributor.author |
Tsepaeva O. |
|
dc.contributor.author |
Nemtarev A. |
|
dc.contributor.author |
Abdullin T. |
|
dc.contributor.author |
Grigor'Eva L. |
|
dc.contributor.author |
Kuznetsova E. |
|
dc.contributor.author |
Akhmadishina R. |
|
dc.contributor.author |
Ziganshina L. |
|
dc.contributor.author |
Cong H. |
|
dc.contributor.author |
Mironov V. |
|
dc.date.accessioned |
2018-04-05T07:09:14Z |
|
dc.date.available |
2018-04-05T07:09:14Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
0163-3864 |
|
dc.identifier.uri |
http://dspace.kpfu.ru/xmlui/handle/net/129597 |
|
dc.description.abstract |
© 2017 The American Chemical Society and American Society of Pharmacognosy. A series of new triphenylphosphonium (TPP) derivatives of the triterpenoid betulin (1, 3-lup-20(29)-ene-3β,28-diol) have been synthesized and evaluated for cytotoxic effects against human breast cancer (MCF-7), prostate adenocarcinoma (PC-3), vinblastine-resistant human breast cancer (MCF-7/Vinb), and human skin fibroblast (HSF) cells. The TPP moiety was applied as a carrier group through the acyl linker at the 28- or 3- and 28-positions of betulin to promote cellular and mitochondrial accumulation of the resultant compounds. A structure-activity relationship study has revealed the essential role of the TPP group in the biological properties of the betulin derivatives produced. The present results showed that a conjugate of betulin with TPP (3) enhanced antiproliferative activity toward vinblastine-resistant MCF-7 cells, with an IC 50 value as low as 0.045 μM. |
|
dc.relation.ispartofseries |
Journal of Natural Products |
|
dc.title |
Design, Synthesis, and Cancer Cell Growth Inhibitory Activity of Triphenylphosphonium Derivatives of the Triterpenoid Betulin |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
8 |
|
dc.relation.ispartofseries-volume |
80 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
2232 |
|
dc.source.id |
SCOPUS01633864-2017-80-8-SID85028342968 |
|